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Background: The Cystic Fibrosis database includes amongst the 1893 gene mutations and polymorphisms a lot of missense mutations, the disease
status of which still remains unproven. In populations with high rates of CFTR mutation heterogeneity, molecular diagnosis is difﬁcult often caus-
ing counseling difﬁculties especially in cases of rare and/or novel mutations.
Methods: Approaches to counseling in cases of novel variants.
Results: Thirty-seven novel variants (4 synonymous, 24 missense, 2 frameshift and 10 intronic substitutions) were identiﬁed and evaluated with the
help of in silico tools.
Conclusions: In a diagnostic environment the answers have to be given within a speciﬁc timeframe, the in silico tools in combination with the
phenotype offer some help but their diagnostic value is limited and cannot be used in isolation for the determination of the severity of the mutation.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; Cystic ﬁbrosis; In silico tools; Novel variants; Clinical phenotype1. Introduction
The cystic fibrosis mutation database currently lists 1893
disease causing variants, with the disease causing effect of
some of them, especially missense mutations, still remaining
unproven. As reported in previous studies [1] the Greek popu-
lation has one of the highest rates of CFTR mutation heteroge-
neity, making molecular diagnosis especially difficult and
causing diagnostic problems especially in cases of rare/novel
mutations. The pathogenicity of novel frameshift mutations,
small insertions/deletions and nonsense variations, can be
more readily explained due to the expected molecular damage
they cause at the protein level. The situation is however compli-
cated with rare missense variations. Their clinical relevance in⁎ Corresponding author at: Department of Medical Genetics, Aghia
Sophia Children's Hospital, Thivon & Levadias, 11527, Athens, Greece.
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doi:10.1016/j.jcf.2012.01.004the field of diagnostics, genotype/phenotype correlation for
the single individual, often raises more questions than answers.
With the use of bioinformatics tools such as SIFT [2],
PolyPhen-2 [3], PMut [4] and Mutation T@sting [5] in combi-
nation with the clinical phenotype, if any, we have attempted to
elucidate the effect of these novel missense variants. Single
nucleotide modifications (SNPs) can also affect normal pre-
mRNA splicing by disrupting consensus sequences or by
creating cryptic splice sequences. This phenomenon has been
observed in the CFTR gene with missense mutations affecting
pre-mRNA splicing [6]. Even synonymous amino acid changes
can impact splicing; therefore the correct interpretation of the
biological consequences of these variants of unknown signifi-
cance is important for molecular diagnostics. For further evalu-
ation of the novel mutations we used the Human Splicing
Finder (HSF) [7], and ESEfinder3.0 [8]. The score for specific
SR proteins, silencer motifs, PESS octamers, that serve as splic-
ing factors changes if a nucleotide change alters the sequence
and disrupts the binding site of the specific proteins. The lastby Elsevier B.V. All rights reserved.
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potential branch points and potential splice sites. There is also
the Alamut software which is an all-in one tool for evaluating
novel variants as it incorporates most of the programs used in
this study; however the license cost makes it unavailable to
our department.
2. Methods
2.1. Subjects
For ease of interpretation we separated the subjects of this
study into three groups: 1) children presenting with a classical
CF phenotype, 2) individuals presenting with atypical or mild
CF phenotype (CFTR related disease) including children and
adults with asthma or bronchiectasis, males presenting with in-
fertility (Congenital Bilateral Absence of Vas Deferens—
CBAVD and Obstructive Azoospermia—OAT) and 3) subjects
of the general population for CFTR screening purposes.
2.2. Methods
The methodology used was DGGE analysis [1,9] and/or
High Resolution Melting Analysis (HRMA) [10] of all coding
sequence including intronic regions surrounding splice sites
allowing coverage of N92% of mutations found in the Greek
population [1,11]. All positive findings were investigated by
direct sequencing [1,9]. All of the reporting is done according
to HGVS (CFTR reference sequences NM_000492.3 and
NG_016465.1) [12].
3. Discussion
In this study we report 37 novel variants in the CFTR gene
(Table 1) found in children presenting with a typical CF
phenotype, in children with a mild/atypical CF phenotype,
males with CBAVD, individuals with asthma and individuals
of the general population. The effects of these changes were
assessed in combination with the clinical phenotype, where
possible and using in silico analysis.
For the establishment of a positive CF diagnosis two disease
causing mutations must be identified in combination with pos-
itive clinical findings [13]. These criteria were fulfilled by three
CF cases that were compound heterozygotes for an already
known CF mutation, in addition to the novel variant (cases 1,
2 and 3, Table 1). In cases 1 and 2, based on the clinical pheno-
type and the nature of the mutations identified we can impose
with certainty a positive CF diagnosis. The azoospermic male
(case 3) (sweat chloride test 90 meq/L) was compound
heterozygote for p.Asn1303Lys [N1303K] and the novel
variant p.Leu541Pro, in trans, described as pathogenic by the
four in silico methods, and predicted to alter enhancer and
silencer motifs (Table 2). In this case we can conclude that
p.Leu541Pro in combination with a severe mutation will result
in a CFTR-related phenotype. Mutation details are presented in
Table 1 as well as the in silico analysis output. Mutation details
as regards the splicing factors are presented in Table 2.All the variants reported were detected only once and were not
found neither in N22,000 normal chromosomes nor in N2000 CF
chromosomes tested in our laboratory during the past years, thus
all novel variants have frequencies a lot less than 0.4% [13,14].
This in combination with the fact that most of them have been
identified in members of the general population makes it very dif-
ficult to deduce whether they are disease causing or extremely
rare polymorphisms. The use of the in silico analysis programs
gives only indications of the nature of these variants and should
not be solely used to make predictions on the clinical severity
of individual CFTR missense mutations [15].
In conclusion we should stress that sequence changes that
haven't been described before pose a serious problem for genetic
counseling. Our laboratory collects samples ranging from chil-
dren with typical CF disease to individuals with no CF-history
seeking CF testing prior to childbearing or during an ongoing
pregnancy. We are a reference lab; therefore the protocol we use
includes screening of the entire CFTR coding sequence. This ap-
proach culminates in finding novel sequence changes. The role of
these changes is difficult to be evaluated with functional analysis
as, in many cases; there is not enough time (i.e. in cases of an on-
going pregnancy). That leaves us with the only option of asses-
sing the variants based on our accumulated experience over the
years and using “in silico” programs only as an indication. The
practice of our laboratory is to report on all findings, stating if a
variant of unknown clinical significance has been identified.
When it comes to counseling the following situations arise:
a) If the novel variant is an undisputed pathogenic (i.e. a frame-
shift mutation identified in a patient exhibiting classic CF
phenotype who also carries a severe CF mutation in trans),
then the family is informed and prenatal diagnosis is offered
to subsequent pregnancies.
b) If the novel variant is identified in a patient referred for test-
ing due to a CFTR-RD phenotype, then depending on their
full genotype (i.e. other mutation in trans known to be dis-
ease causing) we inform them on the possible contribution
of the novel variant to the CFTR-RD phenotype. Prenatal di-
agnosis on subsequent pregnancies it is not advised.
c) If the novel variant is identified in a member of the general
population, it is reported as having unknown clinical signif-
icance and has not been detected in N2000 typical CF chro-
mosomes tested in our laboratory and screening of the other
partner is offered. The factors taken into account in deter-
mining the clinical significance of the unknown variant
are: its position on the CFTR protein; type of the amino
acid change; the protein conservation across species and
the in silico output of at least 3 different prediction pro-
grams. In any case even if the other partner of the couple
is found to be a carrier of a disease causing mutation, during
counseling we stress the possible mildness of the novel var-
iant and prenatal diagnosis is not suggested.
4. Electronic databases
SIFT: http://sift.jcvi.org/
PolyPhen: http://genetics.bwh.harvard.edu/pph/
Table 1
Mutation details and in silico analysis output.
Case Exon or intron (legacy) Nucleotide change Mutation Other ﬁndings Polyphen-2 SIFT Pmut Mutation T@sting Phenotype
1 4 (4) c.405_406dupAC p.Leu136HisfsX18 p.F508del (in trans) N/A N/A N/A Disease causing Classic CF
2 23 (20) c.3815_3816delTG p.Ser1273LeufsX28 p.F508del (in trans) N/A N/A N/A Disease causing Classic CF
3 12 (11) c.1622TNC p.Leu541Pro p.N1303K (in trans) Prob. Dam. NT 0.00 Path. (6) Disease causing Azoospermia
4 17 (15) c.2806CNA p.Pro936Thr p.L1227L Prob. Dam. NT 0.03 Path. (4) Disease causing Inadequate weight gain
5 9 (8) c.1133ANG p.Gln378Arg Prob. Dam. T 0.11 Neut. (6) Disease causing Screening
6 11 (10) c.1484CNA p.Ser945Tyr Prob. Dam. NT 0.00 Path. (2) Disease causing Screening
7 1 (1) c.2TNG p.Met1Arg Prob. Dam. NT 0.00 Path. (7) Disease causing Asthma
8 14 (11) c.1783ANG p.Met595Val Prob. Dam. NT 0.02 Neut. (2) Disease causing Screening
9 24 (21) c.3953TNG p.Val1318Gly Prob. Dam. NT 0.00 Path. (8) Disease causing Azoospermia
10 22 (19) c.3494ANC p.Lys1165Thr Poss. Dam. NT 0.04 Path. (8) Disease causing Bronchitis
11 18 (15) c.2930CNG p.Ser977Cys Poss. Dam. NT 0.01 Path. (5) Disease causing Screening
12 11 (10) c.1561ANT p.Ile521Phe Poss. Dam. NT 0.01 Path. (0) Disease causing CBAVD
13 22 (19) c.3634GNT p.Val1212Phe Poss. Dam. T 0.42 Path. (6) Disease causing Screening
14 8 (7) c.955TNG p.Phe319Val Poss. Dam. T 0.48 Neut. (3) Disease causing Atypical CF
15 14 (13) c.2450GNT p.Gly817Val Benign T 0.31 Path. (4) Polymorphism CBAVD
16 11 (10) c.1472GNC p.Cys491Ser Benign T 0.59 Neut. (3) Disease causing CBAVD
17 8 (7) c.1006ANC p.Ile336Leu Prob. Dam. T 0.19 Neut. (9) Disease causing Screening
18 8 (7) c.913TNG p.Phe305Val Benign T 0.33 Neut. (2) Disease causing Screening
19 11 (10) c.1532CNG p.Ser511Cys Benign T 0.06 Path. (2) Disease causing Screening
20 24 (21) c.3932GNA p.Ser1311Asn Benign T 0.34 Path. (3) Disease causing Screening
21 17 (15) c.2778GNT p.Leu926Phe Benign T 0.24 Path. (5) Disease causing Screening
22 22 (21) c.3674CNT p.Ala1225Val Benign T0.21 Path. (1) Disease causing Screening
23 12 (11) c.1597TNC p.Phe533Leu Benign T0.94 Neut. (6) Disease causing Screening
24 22 (19) c.3627ANC p.Gln1209His p.Asp110Glu (in cis) and
p.Ser737Phe (in trans)
Benign NT 0.02 Path. (5) Disease causing Metabolic alkalosis
25 int14 (13) c.2490+3ANG N/A N/A N/A Polymorphism Screening
26 Int17 (15) c.2909-36TNC N/A N/A N/A Polymorphism Screening
27 int17 (15) c.2909-10TNC N/A N/A N/A Polymorphism Screening
28 int25 (22) c.4137-21GNT N/A N/A N/A Polymorphism Screening
29 int8 (7) c.1116+4ANT N/A N/A N/A Disease causing Screening
30 int18 (16) c.2988+30TNC N/A N/A N/A Polymorphism Screening
31 int12 (11) c.1680-27GNA N/A N/A N/A Polymorphism Screening
32 int15 (14a) c.2620-24CNG N/A N/A N/A Polymorphism Ech. Bowel
33 int15 (14a) c.2620-18delT N/A N/A N/A Polymorphism Screening
34 c.2790-8CNG N/A N/A N/A Obstr. Azoosp.
4 22(19) c.3681ANG p.Leu1227Leu p.P936T N/A N/A N/A Polymorphism Inadequate weight gain
35 22(19) c.3472CNA p.Arg1158Arg N/A N/A N/A polymorphism Oligospermia
36 23 (20) c.3825TNC p.Asp1275Asp N/A N/A N/A Polymorphism Malabs. Synd.
37 8 (7) c.1036CNT p.Leu346Leu N/A N/A N/A Amylasaimia
Abbreviations: N/A: non-applicable, Prob. Dam: probably damaging, Poss. Dam: possibly damaging, NT: not tolerated, T: tolerated, Path: pathological, Neut: neutral, CF: cystic fibrosis, CBAVD: Congenital Bilateral
Absence of the Vas Deferens, Ech. Bowel: echogenic bowel, Obstr. Azoosp.: Obstructive Azoospermia, Malabs. Synd.: malabsorption syndrome.
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Table 2
In silico analysis of the splicing factors.
Mutation Nucleotide change ESEﬁnder (WT/MUT) HSF (WT/MUT) Mutation T@ster (WT/MUT)
p.L541P c.1622TNC Increased score for 5SS_U2_human
(3.48/5.16)/increased score for SC35 (3.48/3.89)
Creation of ESE motifs/creation
and disruption of ESS motifs
Donor gained (0.59)
p.P936T c.2806CNA Decreased score for 5SS_U2_human
(4.07/3.97)/decreased score for SC35 (4.00/2.72)
Increased branch point motif
(53.55/83.18)/disruption of ESE motifs
No change on splice sites
p.Q378R c.1133ANG No change Disruption of ESE motifs/creation of ESS motifs Donor gained (0.94)
p.S945Y c.1484CNA Change for SRp40 best hit (4.6/5.76) Disruption of ESE motifs/disruption of ESS motifs Donor increased (0.30/0.91)
p.M1R c.2TNG Reduced score for SRp55 (4.34/3.51) Disruption of ESE motifs Acceptor lost/donor increased (0.48 /0.56)
p.M595V c.1783ANG No change Donor ss increased (46.9/73.74) if used causes exon skipping.
Disruption of ESE motifs/creation of ESS motifs
Acc increased (0.44/0.50) Acc gained 0.51
p.V1318G c.3953TNG No change New donor site (48.15/74.98) (+55.73%)
if used causes reduction of exon size (−11nt)
Donor increased (0.31/0.99)
p.K1165T c.3494ANC No change Minor changes No change
p.S977C c.2930CNG No change Minor changes No change
p.I521F c.1561ANT No change Minor changes No change
p.V1212F c.3634GNT No change Disruption of ESE motifs Donor gained 0.36
p.F319V c.955TNG No change Minor changes Acc increased (0.42/0.61)
p.G817V c.2450GNT No change Minor changes No change
p.C491S c.1472GNC No change Disruption of ESE motifs Acceptor sites created
p.I336L c.1006ANC No change Disruption of ESE motifs No change
p.F305V c.913TNG Increased score for SRp55 Disruption of ESS motifs Donor gained (0.99)
p.S511C c.1532CNG Decreased score for SC35 Disruption of ESS motifs No change
p.S1311N c.3932GNA Changes on ss scores Disruption of ESS motifs Donor increased (0.50/0.63)
p.L926F c.2778GNT No change Creation of ESS motifs Changes on ss scores
p.A1225V c.3674CNT No change Disruption of ESE motif/creation of ESS motif Donor increased (0.72/0.99)
p.F533L c.1597TNC No change Creation of ESE motifs/disruption of ESS motifs No change
p.Q1209H c.3627ANC No change Minor changes No change
c.2490+3ANG No change Minor changes No change
c.2909-36TNC Decrease of donor ss Disruption of ESS motifs Acc increased (0.33/0.48)/donor increased (0.74/0.94)
c.2909-10TNC Change for SRp55 best hit (3.97/5.16) Disruption of ESS motifs No change
c.4137-21GNT No change Disruption of ESE and creation of ESS motifs Acc increased (0.86/0.96)
c.1116+4ANT No change WT donor site disrupted Marginal changes on donor ss
c.2988+30TNC No change Disruption of ESE motif/creation of ESS motif No change
c.1680-27GNA No change Disruption of ESS motifs No change
c.2620-24CNG No change Creation of ESE motifs Donor gained 0.96
c.2620-18delT No change New donor ss/changes on ESE and ESS motifs Acc increased (0.41/0.55)
c.2658-8CNG Decreased score for acc site Minor changes Marginal changes on ss
p.L1227L c.3681ANG No change Changes on ESE and ESS motifs No change
p.R1158R c.3472CNA No change Creation of ESE motifs/creation
of ESS motifs
Marginal changes on ss
p.D1275D c.3825TNC No change No change Donor increased (0.56/0.87)
p.L346L c.1036CNT No change No change No change
Abbreviations: ESE: exonic splicing enhancer, HSF: human splicing finder, ESS: exonic splicing silencer, WT: wild type, Mut: mutant, ss: splicing site.
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HSF: http://www.umd.be/HSF/
ESEfinder3.0: http://rulai.cshl.edu/cgi-bin/tools/ESE3/ese
finder.cgi
Mutation Taster: http://www.mutationtaster.org/
Cystic Fibrosis Mutation Database: http://www.genet.sickkids.
on.ca
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